Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 523-528

  An, In Sook ^a   An, Sungkwan ^a   Kwon, Ku Jung ^a   Kim, Young Joo ^b   Bae, Seunghee ^a  

^a Konkuk University   (South Korea)

^b Osan University   (South Korea)

Author keywords

A549 cells; Cell viability; Ginsenoside Rh2; Human non small cell lung cancer; MicroRNA

Indexed keywords

GINSENOSIDE RH 2; MICRORNA;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN A549; CELL VIABILITY; CHROMATIN; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHI-SQUARE DISTRIBUTION; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HUMANS; LUNG NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STATISTICS, NONPARAMETRIC; UP-REGULATION;

EID: 84872802770     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2136     Document Type: Article

References (26)

1. Walker S: Updates in non-small cell lung cancer. Clin J Oncol Nurs 12: 587-596, 2008.
2. Gong HC, Wang S, Mayer G, et al: Signatures of drug sensitivity in nonsmall cell lung cancer. Int J Proteomics: August 7, 2011 (Epub ahead of print). doi:10.1155/2011/215496).
3. Ramalingam S and Belani CP: Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 11: 245-257, 2007. (Pubitemid 46188817)
4. Ambros V: microRNAs: tiny regulators with great potential. Cell 107: 823-826, 2001. (Pubitemid 34084973)
5. Ceppi P, Mudduluru G, Kumarswamy R, et al: Loss of miR-200c expression induces an aggressive, invasive and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216, 2010.
6. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704, 2008.
7. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411: 846-852, 2010.
8. Zhu X, Li H, Long L, et al: miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) 44: 519-526, 2012.
9. Shibata S: Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci (Suppl 16): S28-S37, 2001.
10. Bi WY, Fu BD, Shen HQ, et al: Sulfated derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7 macrophages. Inflammation 35: 1659-1668, 2012.
11. He L, Lee J, Jang JH, et al: Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-kappaB, NFATc1 and c-Fos. Bone 50: 1207-1213, 2012.
12. Luo JZ and Luo L: Ginseng on hyperglycemia: effects and mechanisms. Evid Based Complement Alternat Med 6: 423-427, 2009.
13. Wu N, Wu GC, Hu R, Li M and Feng H: Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin 32: 345-353, 2011.
14. Li B, Zhao J, Wang CZ, et al: Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 301: 185-192, 2011.
15. Zhang C, Yu H and Hou J: Effects of 20 (S) -ginsenoside Rh2 and 20 (R) -ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells. Zhongguo Zhong Yao Za Zhi 36: 1670-1674, 2011 (In Chinese).
16. Cheng CC, Yang SM, Huang CY, Chen JC, Chang WM and Hsu SL: Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol 55: 531-540, 2005.
17. Li Q, Li Y, Wang X, et al: Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog 50: 760-769, 2011.
18. Jia WW, Bu X, Philips D, et al: Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82: 431-437, 2004. (Pubitemid 39388382)
19. Hu S, Yu JY, Xiong LJ, Hu CP and Zhang YX: Research on the mechanism of ginsenoside Rh2 reversing the resistance of lung adenocarcinoma cells to cisplatin. Zhonghua Yi Xue Za Zhi 90: 264-268, 2010 (In Chinese).
20. Hummel R, Watson DI, Smith C, et al: Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 15: 429-438, 2011.
21. Fujita Y, Kojima K, Ohhashi R, et al: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285: 19076-19084, 2010.
22. Lehmann U, Hasemeier B, Christgen M, et al: Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214: 17-24, 2008.
23. Zheng B, Liang L, Wang C, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17: 7574-7583, 2011.
24. Zhang H, Li Y, Huang Q, et al: MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ 18: 1702-1710, 2011.
25. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126, 2007. (Pubitemid 46357525)
26. Yue PY, Mak NK, Cheng YK, et al: Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med 2: 6, 2007.